Eric Dudenhoefer, MD
Ophthalmology · Sandusky, OHNPI 1679511935
Payments from drug & device makers
Across 113 payments — averaging $45.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ivantis, Inc$3K
- Alcon$709
- AbbVie$469
- Regeneron Healthcare Solutions, Inc.$140
- Tarsus Pharmaceuticals, Inc.$128
- Amgen$124
- plus $772 from 19 others
What the payments were for
- Consulting fees$2,00039%
- Food & beverage$3,12861%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ivantis, Inc | 17 | $2,786 |
| Alcon | 23 | $709 |
| AbbVie(2 entities) | 22 | $469 |
| Regeneron Healthcare Solutions, Inc. | 2 | $140 |
| Tarsus Pharmaceuticals, Inc. | 6 | $128 |
| Amgen | 7 | $124 |
| Biotissue Holdings Inc. | 6 | $116 |
| Bausch Health US, LLC | 1 | $102 |
| Dompe US, Inc. | 4 | $82 |
| Bausch & Lomb Americas Inc. | 3 | $59 |
| Novartis | 2 | $55 |
| Sun Pharmaceutical Industries Inc. | 3 | $44 |
| Oyster Point Pharma, Inc. | 2 | $42 |
| Sight Sciences, Inc. | 2 | $41 |
| Harrow Eye, LLC | 2 | $41 |
| Kala Pharmaceuticals, Inc. | 2 | $30 |
| Glaukos Corporation | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Thea Pharma Inc. | 1 | $22 |
| American Regent | 1 | $20 |
| Rayner Intraocular Lenses Limited | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $15 |
| GSK | 1 | $15 |
| Aerie Pharmaceuticals, Inc. | 1 | $13 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Hydrus Microstent$1,910
- Hydrus$757
- EYLEA$125
- RESTASIS$124
How this compares
$5,128 in reported general payments places this provider in the 80th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 32 | $43,483 |
| XiidraLifitegrast | 18 | $25,527 |
| Cyclosporine | 20 | $17,154 |
| LumiganBimatoprost | 23 | $8,975 |
| MoxifloxacinMoxifloxacin Hcl | 91 | $5,825 |
| Loteprednol Etabonate | 34 | $5,499 |
| Prednisolone Acetate | 154 | $5,184 |
| Timolol Maleate | 98 | $3,928 |
| Famciclovir | 11 | $2,983 |
| Latanoprost | 171 | $2,731 |
| Bimatoprost | 14 | $1,866 |
| Fluorometholone | 17 | $1,611 |
| Gatifloxacin | 15 | $654 |
| Acyclovir | 30 | $549 |
| ValacyclovirValacyclovir Hcl | 11 | $527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $469 | $52,45855 claims |
| Bausch & Lomb Americas Inc.Xiidra | $59 | $25,52718 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $15 | $5,49934 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Sandusky
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
- Jonathan LassCleveland$1.9M
- William WileyCleveland$1.9M
- Peter KaiserCleveland$1.5M
- David RogersColumbus$1.5M
- Michael SnyderCincinnati$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.